Lymphoma

Results will likely "encourage a practice change," editorialists say

News, features, and commentary about cancer-related issues

Findings may bolster interest in BTK inhibitors for autoimmune diseases

Adding polatuzumab vedotin to a modified version of R-CHOP significantly improved PFS

Research suggests cancer-specific precision monitoring and risk stratification

Omidubicel reduced infections in blood cancer patients from 60% to 39% at 100 days posttransplant

News, features, and commentary about cancer-related issues

DLBCL patients with HF 45% less likely to receive standard first-line anthracyclines, study found

The actor noticed swollen glands while on tour for "Jurassic World Dominion"

News, features, and commentary about cancer-related issues

POLARIX trial supports a favorable risk-benefit profile for polatuzumab vedotin, ODAC members say

News, features, and commentary about cancer-related issues

Ahead of ODAC meeting, agency reviewers suggest modest PFS results in POLARIX "raise uncertainty"

More than 1,300 cases and 35 deaths, as reports of other implant-linked malignancies emerge